Active Ingredient History
Naltrexone is marketed as its hydrochloride salt, naltrexone hydrochloride, under the trade names Revia and Depade. A once-monthly extended-release injectable formulation is marketed under the trade name Vivitrol. VIVITROL is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL. VIVITROL is indicated for the prevention of relapse to opioid dependence, following opioid detoxification. Naltrexone is a pure opiate antagonist and has little or no agonist activity. The mechanism of action of naltrexone in alcoholism is not understood; however, involvement of the endogenous opioid system is suggested by preclinical data. Naltrexone is thought to act as a competitive antagonist at mc, κ, and δ receptors in the CNS, with the highest affinity for the μ receptor. Naltrexone competitively binds to such receptors and may block the effects of endogenous opioids. This leads to the antagonization of most of the subjective and objective effects of opiates, including respiratory depression, miosis, euphoria, and drug craving. The major metabolite of naltrexone, 6-β-naltrexol, is also an opiate antagonist and may contribute to the antagonistic activity of the drug. Low dose naltrexone is an “off label” use of naltrexone. Normal naltrexone usage to break addictions is 50mg – 100mg. Usage of low dose naltrexone ranges in the area of 3 mg – 4.5 mg dosing and is prescribed in an oral pill form and is quite inexpensive. For people with multiple sclerosis, the dosage of LDN ranges from 1.5 to 4.5 ml per day. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alcoholism (approved 2006)
Opioid-Related Disorders (approved 2006)
Acne Vulgaris (Phase 3)
Acquired Immunodeficiency Syndrome (Phase 1/Phase 2)
Adolescent (Phase 2/Phase 3)
Aging (Phase 2)
Alcohol Drinking (Phase 4)
Alcoholic Intoxication (Phase 4)
Alcohol-Induced Disorders (Phase 4)
Alcoholism ()
Alcohol-Related Disorders (Phase 4)
Allergy and Immunology (Phase 1)
Alopecia (Phase 2)
Alopecia Areata (Phase 3)
Altitude (Phase 4)
Amphetamine-Related Disorders (Phase 3)
Analgesia (Phase 1)
Analgesics, Opioid (Phase 2/Phase 3)
Anemia (Phase 2)
Anemia, Aplastic (Phase 2)
Anemia, Diamond-Blackfan (Phase 2)
Anemia, Refractory (Phase 3)
Anemia, Sickle Cell (Phase 2)
Aneurysm (Phase 3)
Anorexia (Phase 2/Phase 3)
Antiretroviral Therapy, Highly Active (Phase 2)
Arthritis (Phase 4)
Arthritis, Experimental (Phase 2)
Arthritis, Juvenile (Phase 4)
Arthritis, Psoriatic (Phase 4)
Arthritis, Rheumatoid (Phase 4)
Arthropathy, Neurogenic (Phase 3)
Asthma (Phase 3)
Atherosclerosis (Phase 3)
Autoimmune Diseases (Phase 3)
Back Pain (Phase 2)
Bariatric Surgery (Phase 4)
Basal Cell Nevus Syndrome (Phase 2)
Behavior, Addictive (Phase 4)
beta-Thalassemia (Phase 4)
Binge Drinking (Phase 2)
Binge-Eating Disorder (Phase 2/Phase 3)
Biological Availability (Phase 1)
Bipolar Disorder (Phase 4)
Blood Pressure (Phase 4)
Bone Marrow Cells (Phase 1/Phase 2)
Bone Marrow Transplantation (Phase 3)
Borderline Personality Disorder (Phase 3)
Brain Neoplasms (Phase 3)
Breast Carcinoma In Situ (Phase 2)
Breast Neoplasms (Phase 3)
Bulimia (Early Phase 1)
Bulimia Nervosa (Phase 2/Phase 3)
Buprenorphine (Phase 2)
Burkitt Lymphoma (Phase 4)
Cancer Pain (Phase 3)
Cannabis (Phase 2)
Carcinoma, Intraductal, Noninfiltrating (Phase 2)
Carcinoma, Lobular (Phase 2)
Carcinoma, Renal Cell (Phase 3)
Carcinoma, Squamous Cell (Phase 3)
Carcinoma, Transitional Cell (Phase 2)
Cardiotoxicity (Phase 3)
Cardiovascular Diseases (Phase 4)
Central Nervous System Stimulants (Phase 4)
Central Serous Chorioretinopathy (Phase 2)
Charcot-Marie-Tooth Disease (Phase 3)
Child (Phase 2)
Child Mortality (Phase 1)
Choriocarcinoma (Phase 3)
Choroid Plexus Neoplasms (Phase 3)
Chronic Disease (Phase 4)
Chronic Pain (Phase 4)
Chronic Urticaria (Phase 3)
Churg-Strauss Syndrome (Phase 4)
Cigarette Smoking (Phase 4)
Cocaine-Related Disorders (Phase 3)
Cognition (Early Phase 1)
Cognition Disorders (Phase 2)
Colitis, Ulcerative (Phase 4)
Colorectal Neoplasms (Phase 2)
Coronary Artery Disease (Phase 2)
Coronary Disease (Phase 2)
Coronavirus Infections (Phase 2)
COVID-19 (Phase 3)
Crohn Disease (Phase 4)
Cystitis, Interstitial (Phase 4)
Demyelinating Diseases (Phase 4)
Depression (Phase 4)
Depressive Disorder (Phase 2)
Depressive Disorder, Major (Phase 4)
Depressive Disorder, Treatment-Resistant (Phase 1)
Dermatitis (Phase 2)
Dermatitis, Atopic (Phase 3)
Dermatomyositis (Phase 3)
Diabetes Mellitus, Type 1 (Phase 1/Phase 2)
Diabetes Mellitus, Type 2 (Phase 4)
Dissociative Disorders (Phase 2)
Down Syndrome (Phase 3)
Drug Combinations (Phase 4)
Drug Therapy (Phase 2)
Dry Eye Syndromes (Phase 2)
Electrocardiography (Phase 1)
Endometriosis (Phase 3)
Enteropathy-Associated T-Cell Lymphoma (Phase 4)
Eosinophilic Granuloma (Phase 2)
Ependymoma (Phase 2/Phase 3)
Exergaming (Phase 2)
Eye-Tracking Technology (Phase 2)
Facial Pain (Phase 2/Phase 3)
Fanconi Anemia (Phase 1)
Fatigue Syndrome, Chronic (Phase 2)
Fear (Early Phase 1)
Feeding and Eating Disorders (Phase 4)
Fibromyalgia (Phase 4)
Firesetting Behavior (Phase 2)
Fusion Proteins, bcr-abl (Phase 2)
Gambling (Phase 4)
Geriatrics (Phase 3)
Gestational Trophoblastic Disease (Phase 3)
Giant Cell Arteritis (Phase 3)
Glioma (Phase 2)
Glycogen Storage Disease Type II (Phase 4)
Graft vs Host Disease (Phase 4)
Granuloma (Phase 3)
Granulomatosis with Polyangiitis (Phase 4)
Graves Ophthalmopathy (Phase 4)
Growth and Development (Phase 1/Phase 2)
Gulf War (Phase 2)
Headache (Phase 1/Phase 2)
Head and Neck Neoplasms (Phase 3)
Healthy Volunteers (Phase 4)
Hearing Loss, Sensorineural (Phase 3)
Heart Diseases (Phase 1)
Heart Failure (Phase 2/Phase 3)
Helminthiasis (Phase 4)
Hematologic Neoplasms (Phase 2)
Hematopoietic Stem Cell Transplantation (Phase 2)
Hemoglobinuria, Paroxysmal (Phase 2)
Hepatitis (Phase 4)
Hepatitis B, Chronic (Phase 1/Phase 2)
Heroin Dependence (Phase 4)
Histiocytosis, Langerhans-Cell (Phase 2/Phase 3)
HIV (Phase 4)
HIV Infections (Phase 4)
HIV Seropositivity (Phase 2)
Hodgkin Disease (Phase 3)
Hydatidiform Mole (Phase 3)
Hypoglycemia (Phase 1/Phase 2)
Immune System Diseases (Phase 2)
Impulsive Behavior (Phase 2/Phase 3)
Infections (Phase 2)
Inflammation (Phase 3)
Inflammatory Bowel Diseases (Phase 2)
Intellectual Disability (Phase 3)
Intestinal Neoplasms (Phase 2)
Intraocular Lymphoma (Phase 2)
Kidney Neoplasms (Phase 2)
Leukemia (Phase 3)
Leukemia, B-Cell (Phase 2)
Leukemia, Biphenotypic, Acute (Phase 3)
Leukemia, Eosinophilic, Acute (Phase 2)
Leukemia, Hairy Cell (Phase 2)
Leukemia, Large Granular Lymphocytic (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 4)
Leukemia, Lymphoid (Phase 4)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Megakaryoblastic, Acute (Phase 1/Phase 2)
Leukemia, Monocytic, Acute (Phase 3)
Leukemia, Myeloid (Phase 3)
Leukemia, Myeloid, Acute (Phase 4)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Leukemia, Myelomonocytic, Acute (Phase 3)
Leukemia, Myelomonocytic, Chronic (Phase 3)
Leukemia, Myelomonocytic, Juvenile (Phase 2)
Leukemia, Neutrophilic, Chronic (Phase 2)
Leukemia, Plasma Cell (Phase 1)
Leukemia, Prolymphocytic (Phase 1/Phase 2)
Leukemia, Promyelocytic, Acute (Phase 4)
Leukemia, T-Cell (Phase 2)
Lichen Planus (Phase 2)
Liver Cirrhosis, Biliary (Phase 3)
Low Back Pain (Phase 2)
Lung Diseases (Phase 2)
Lupus Erythematosus, Systemic (Phase 3)
Lymphohistiocytosis, Hemophagocytic (Phase 2)
Lymphoma (Phase 4)
Lymphoma, AIDS-Related (Phase 2)
Lymphoma, B-Cell (Phase 4)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Extranodal NK-T-Cell (Phase 3)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Anaplastic (Phase 4)
Lymphoma, Large-Cell, Immunoblastic (Phase 3)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 3)
Lymphoma, T-Cell (Phase 4)
Lymphoma, T-Cell, Cutaneous (Phase 4)
Lymphoma, T-Cell, Peripheral (Phase 2)
Lymphomatoid Granulomatosis (Phase 2)
Lymphoproliferative Disorders (Phase 2)
Macular Edema (Phase 4)
Malaria (Phase 1)
Marijuana Abuse (Phase 2)
Marijuana Smoking (Phase 2)
Marijuana Use (Phase 2)
Mediastinal Neoplasms (Phase 4)
Medication Adherence (Phase 4)
Medicine, Chinese Traditional (Phase 2/Phase 3)
Medulloblastoma (Phase 3)
Melanoma (Phase 2)
Meningeal Carcinomatosis (Phase 4)
Meningeal Neoplasms (Phase 4)
Meninges (Phase 2)
Mental Disorders (Phase 4)
Mesothelioma (Phase 2)
Mesothelioma, Malignant (Phase 2)
Methadone (Phase 2)
Methamphetamine (Phase 3)
Methotrexate (Phase 4)
Microscopic Polyangiitis (Phase 4)
Migraine Disorders (Phase 2)
Migraine with Aura (Phase 2)
Migraine without Aura (Phase 2)
Mucopolysaccharidoses (Phase 2/Phase 3)
Mucositis (Phase 3)
Multiple Myeloma (Phase 3)
Multiple Sclerosis (Phase 4)
Multiple Sclerosis, Relapsing-Remitting (Phase 4)
Mutation (Phase 1/Phase 2)
Myasthenia Gravis (Phase 2)
Mycosis Fungoides (Phase 4)
Myelitis (Phase 4)
Myelodysplastic Syndromes (Phase 3)
Myeloproliferative Disorders (Phase 3)
Myocardial Infarction (Phase 2)
Myocardial Ischemia (Phase 2/Phase 3)
Naltrexone (Phase 4)
Narcotic-Related Disorders (Phase 1)
Neck Pain (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasm, Residual (Phase 2)
Neoplasms (Phase 2)
Neoplasms, Germ Cell and Embryonal (Phase 3)
Neoplasms, Plasma Cell (Phase 2)
Neuralgia (Phase 2/Phase 3)
Neuritis (Phase 4)
Neuroblastoma (Phase 2)
Neuroectodermal Tumors (Phase 3)
Neuroendocrine Tumors (Phase 2)
Neurofibromatosis 1 (Phase 2)
Neutropenia (Phase 2)
Obesity (Phase 4)
Obesity, Morbid (Phase 4)
Obsessive-Compulsive Disorder (Phase 2)
Opiate Alkaloids (Phase 1)
Opiate Overdose (Phase 2)
Opioid-Related Disorders (Phase 4)
Optic Neuritis (Phase 4)
Osteoarthritis (Phase 3)
Osteopetrosis (Phase 2/Phase 3)
Osteosarcoma (Phase 3)
Ototoxicity (Phase 2)
Ovarian Neoplasms (Phase 2)
Overweight (Phase 3)
Pain ()
Pain, Postoperative (Phase 1)
Parkinson Disease (Phase 4)
Pediatrics (Phase 1)
Pemphigoid, Bullous (Phase 3)
Pharmacokinetics (Phase 1)
Placebos (Phase 4)
Plasmablastic Lymphoma (Phase 1/Phase 2)
Plasmacytoma (Phase 2)
Polyarteritis Nodosa (Phase 4)
Polycystic Ovary Syndrome (Phase 1)
Polycythemia Vera (Phase 2)
Polymyositis (Phase 3)
Precancerous Conditions (Phase 2)
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)
Pregnancy Complications (Phase 3)
Pregnancy, Ectopic (Phase 4)
Pregnancy, Unwanted (Phase 4)
Primary Myelofibrosis (Phase 2)
Prolonged Grief Disorder (Phase 4)
Prostatic Neoplasms (Phase 2)
Pruritus (Phase 2)
Psoriasis (Phase 4)
Psychotic Disorders (Phase 4)
Quality of Life (Phase 2)
Radiculopathy (Phase 2)
Randomized Controlled Trial (Phase 4)
Recurrence (Phase 2)
Respiratory Distress Syndrome (Phase 2)
Retinoblastoma (Phase 2)
Retroperitoneal Fibrosis (Phase 3)
Rhabdoid Tumor (Phase 3)
Sarcoidosis (Phase 4)
Sarcoma (Phase 3)
Schizophrenia (Phase 4)
Scleroderma, Systemic (Phase 1/Phase 2)
Self-Injurious Behavior (Phase 4)
Self Mutilation (Phase 4)
Severe Acute Respiratory Syndrome (Phase 2)
Severe Combined Immunodeficiency (Phase 2)
Sexual Health (Phase 2)
Sezary Syndrome (Phase 2)
Shwachman-Diamond Syndrome (Phase 2)
Sleep Apnea, Central (Phase 4)
Smoking (Phase 4)
Smoking Cessation (Phase 2)
Spondylarthropathies (Phase 4)
Spondylitis, Ankylosing (Phase 4)
Squamous Cell Carcinoma of Head and Neck (Phase 3)
Stem Cell Transplantation (Phase 2)
Still's Disease, Adult-Onset (Phase 2)
Stomach Neoplasms (Phase 3)
Stress Disorders, Post-Traumatic (Phase 4)
Substance Abuse, Oral (Phase 4)
Substance-Related Disorders (Phase 4)
Substance Withdrawal Syndrome (Phase 3)
Survival (Phase 3)
Synovitis (Phase 2)
Takayasu Arteritis (Phase 3)
Testicular Neoplasms (Phase 3)
Thrombocythemia, Essential (Phase 2)
Thrombocytopenia (Phase 2)
Tissue Donors (Phase 2)
Tobacco Use Disorder (Phase 3)
Translocation, Genetic (Phase 2)
Transplantation (Phase 3)
Trichotillomania (Phase 2)
Tuberculosis (Phase 4)
Ureteral Neoplasms (Phase 2)
Urethral Neoplasms (Phase 3)
Urinary Bladder Neoplasms (Phase 3)
Urticaria (Phase 2)
Uterine Cervical Neoplasms (Phase 3)
Uterine Neoplasms (Phase 3)
Uveitis (Phase 4)
Uveitis, Intermediate (Phase 3)
Vasculitis (Phase 4)
Veterans (Phase 4)
Vulvodynia (Phase 2)
Waldenstrom Macroglobulinemia (Phase 2)
Wiskott-Aldrich Syndrome (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
